Literature DB >> 24359139

Surface markers of cancer stem cells in solid tumors.

Pu Xia1.   

Abstract

Cancer stem cells (CSCs) are a small subpopulation of cells within tumors with capabilities of self-renewal, differentiation, and tumorigenicity. Successful cancer treatment would need to eliminate CSCs. The CSCs can be identified and isolated by both CSC-specific cell surface marker expression and functional assay, such as floating spheres, and aldehyde dehydrogenase (ALDH) activity assay. However, lack of universal expression of surface markers limits their usage to identify CSCs. Here, we give a brief overview of the current known surface markers of CSCs and associated tumor types. Finally, the possible reasons for contradiction are discussed in these surface markers. In this review, I not only provide an overview of the current known surface markers but also highlight the importance of achieving maximal accuracy of a new marker.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24359139     DOI: 10.2174/1574888x09666131217003709

Source DB:  PubMed          Journal:  Curr Stem Cell Res Ther        ISSN: 1574-888X            Impact factor:   3.828


  26 in total

Review 1.  PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application.

Authors:  Pu Xia; Xiao-Yan Xu
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 2.  Integrative Analysis of CD133 mRNA in Human Cancers Based on Data Mining.

Authors:  Gui-Min Wen; Fei-Fei Mou; Wei Hou; Dan Wang; Pu Xia
Journal:  Stem Cell Rev Rep       Date:  2019-02       Impact factor: 5.739

3.  Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells.

Authors:  Kavitha Sivasubramaniyan; Abhishek Harichandan; Karin Schilbach; Andreas F Mack; Jens Bedke; Arnulf Stenzl; Lothar Kanz; Gerhard Niederfellner; Hans-Jörg Bühring
Journal:  Glycobiology       Date:  2015-05-15       Impact factor: 4.313

4.  CD133 mRNA may be a suitable prognostic marker for human breast cancer.

Authors:  Pu Xia
Journal:  Stem Cell Investig       Date:  2017-11-07

Review 5.  Potentials of lncRNA-miRNA-mRNA networks as biomarkers for laryngeal squamous cell carcinoma.

Authors:  Yan Lv; Yanhua Wang; Zhikai Zhang
Journal:  Hum Cell       Date:  2022-10-01       Impact factor: 4.374

6.  Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells.

Authors:  Ming Liu; Weiyi Zhang; Wei Tang; Yanjuan Wang; Xingzeng Zhao; Xiangyun Wang; Xin Qi; Jing Li
Journal:  Tumour Biol       Date:  2015-09-02

7.  Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines.

Authors:  Alena Nunukova; Jakub Neradil; Jan Skoda; Josef Jaros; Ales Hampl; Jaroslav Sterba; Renata Veselska
Journal:  Int J Mol Med       Date:  2015-05-14       Impact factor: 4.101

Review 8.  Stem cell-derived exosomes: roles in stromal remodeling, tumor progression, and cancer immunotherapy.

Authors:  Farah Fatima; Muhammad Nawaz
Journal:  Chin J Cancer       Date:  2015-09-14

9.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30

Review 10.  Renal Cancer Stem Cells: Characterization and Targeted Therapies.

Authors:  Anna Julie Peired; Alessandro Sisti; Paola Romagnani
Journal:  Stem Cells Int       Date:  2016-05-15       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.